Spectacles that use SightGlass Vision’s trademarked Diffusion Optics Technology have demonstrated efficacy in slowing the progression of myopia in children, based on 24-month interim data from its pivotal multisite clinical study.
The data from the CYPRESS trial, now in its third year, was presented this week at the Association for Research in Vision and Ophthalmology (ARVO) annual conference in Denver.
An analysis of full-time wearers – children aged six to 10 at initiation whose parents reported that they did not remove the study spectacles for near vision activities – showed statistically significant improvements between groups using Diffusion Optics Technology lenses and the control, SightGlass Vision said.
Axial length exhibited a 0.21 mm difference, and the spherical equivalent refraction difference was 0.52 dioptres (D).
Study investigators enrolled, randomised, and dispensed the lenses to 256 eligible children across 14 clinical trial sites in the US and Canada – in what was said to be a geographical distinction compared to most other myopia-related spectacle lens studies.
At the time of enrolment, subjects were six to 10 years old having myopia between -0.75 D and -4.50 D.
With a mean age of 8.1 years at screening, the CYPRESS cohort is younger than children in other well-known myopia management studies. According to SightGlass Vision, given the higher likelihood of spectacles-based interventions for younger children, this study parameter should help build confidence in prescribers and families.
Additional analysis of younger wearers will be presented at the Nederlands Contact Lens Congress (NCC) in June.
Spectacle lenses using patent-protected SightGlass Vision Diffusion Optics Technology incorporate thousands of micro-dots that softly scatter light to reduce contrast on the retina – a method intended to reduce myopia progression in children.
Founded in 2016, SightGlass Vision now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialisation opportunities and expand the myopia management category worldwide.
SightGlass Vision CEO Mr Andrew Sedgwick said the company’s spectacle lenses, with their unique mechanism of action, represent a promising new approach to myopia control.
“We’re enthusiastic about sharing more detail from the two-year interim results, which will further support our development efforts and ongoing commercialisation activities in select markets,” he said.
The last several decades have seen a steady rise in the prevalence of myopia worldwide. Today affecting 2.6 billion people globally, it is estimated that nearly five billion people – half the world’s population – will be myopic by 2050.
More reading
EssilorLuxottica-CooperCompanies myopia specs joint venture ‘comes to life’
New data confirms it’s never too late to start myopia treatment
WCO and CooperVision develop myopia management resource
